Click on a faculty member's name for a detailed description of their research.

Rami G. Azrak, Instructor, M.D., Syria. In vitro studies to identify molecular changes associated with tumor progression and therapy. 

Terry A. Beerman, Professor Emeritus, Ph.D., Syracuse U. Study of cellular responses to DNA damage induced by anti-tumor agents. Study/development of novel sequence specific DNA binding agents as inhibitors of gene expression.

Ralph Bernacki, Professor Emeritus, Ph.D., U. Rochester. Preclinical anticancer drug development, tumor metastasis and angiogenesis, study of cell surface complex carbohydrates, modulation of drug resistance.

Adrian R. Black, Assistant Professor, Ph.D., U. London. Transcription factors in tumor progression, cell cycle regulatory molecules as targets for chemotherapy.

Jennifer Black, Professor, Ph.D., U. London. Signal transduction, protein kinase C, control of cell growth/cell cycle progression and differentiation in the intestinal epithelium, cell ultrastructure.

Moray J. Campbell, Associate Professor & Director of Graduate Studies, Ph.D., U Kent. Defining, modeling and exploiting epigenetic disruption to nuclear receptor signaling in solid tumors.

Dhyan Chandra, Assistant Professor, Ph.D., Jawaharlal Nehru University. Heat-shock proteins and cell survival, metochondrial fragmentation and caspase activation, apoptosis signaling in cancer stem cells.

Gokul Das, Assistant Professor,  Ph.D., Baylor College of Medicine. Tumor suppressor protein p53/transcriptional regulation/genomic damage, DNA repair, and cell cycle control/interaction between p53 and estrogen receptor signaling pathways.

Bruce J. Dolnick, Professor, Ph.D., SUNY at Buffalo. The rTS signaling pathway in growth regulation and experimental chemotherapy.

Marwan Fakih, Associate Professor, M.D., American University of Beirut, Lebanon. Developmental therapeutics and colorectal cancer.

Barbara Foster, Assistant Professor, Ph.D., UC San Francisco. Prostate cancer; transgenic mouse models; prostate cancer/bone interaction; preclinical testing of novel therapeutic approaches for prevention and treatment of prostate cancer.

David Goodrich, Professor & Chair of the Graduate Program, Ph.D., UC Berkeley. Elucidating molecular mechanisms underlying tumor suppression by the Rb1 gene, particularly in cell cycle regulation with the aim of targeting this pathway in therapy.

William R. Greco, Professor, Ph.D., SUNY at Buffalo. Pharmacometrics and Bioinformatics.

Wendy Huss, Assistant Professor, Ph.D., Baylor College of Medicine. Targeting the prostate tumor stem cell therapeutically in effort to eliminate the source of recurrent prostate cancer.

Margot M. Ip, Professor Emeritus, Ph.D., U. Wisconsin. Chemoprevention of breast cancer, tumor necrosis factor and its role in normal and malignant breast, stromal-epithelial interactions in normal and malignant breast.

Candace S. Johnson, Professor,  Ph.D., Ohio State University. Drug development of novel agents; preclinical tumor models; mechanistic studies on drugs with novel targets; steroid hormones and their potential as an antiproliferative agent and development of novel approaches in prostate cancer.

Adam R. Karpf,  Associate Professor, Ph.D., UT Austin. The role of DNA methylation and DNA methyltransferase enzymes in oncogenesis with the overall aim of exploiting this biochemical pathway as a cancer drug target.

Fengzhi Li, Associate Professor, Ph.D., Beijing. Mechanism of anti-apoptotic protein function and regulation in cancer cells.

John McGuire, Professor, Ph.D., UC Berkeley. Biochemistry of folic acid and one-carbon metabolism, biochemical pharmacology of new and established antifolates, drug resistance.

Enrico Mihich, Professor Emeritus, M.D., U. Milan. Experimental tumor therapeutics; relationships between cancer chemotherapy and immunity; biochemical bases for selective toxicity; preclinical pharmacology and toxicology of antitumor agents.

Carl Porter, Professor Emeritus, Ph.D., SUNY at Buffalo. New and novel anticancer targets, biological role of polyamines in cell proliferation, drug discovery and development, mechanisms of cell cycle and apoptosis control.

Youcef Rustum, Professor, Ph.D., SUNY at Buffalo. Clinical biochemistry and pharmacology, with emphasis on selective actions of antitumor agents.

Harry Slocum, Assistant Professor, Ph.D., SUNY at Buffalo. Cell biology of human solid tumors, cell interaction and growth control, cellular heterogeneity, mechanism of action of anticancer agents.

Robert Straubinger, Professor, Ph.D., UC San Francisco. Cell biology and biophysics of membranes and membrane function; use of liposomal drug carriers to improve the efficacy of cancer therapeutics.

Janice Sufrin, Associate Professor, Ph.D., Brandeis U. Structure-based design/synthesis and biochemical/therapeutic effects of molecules that target S-adenosylmethionine-associated pathways, with particular emphasis on methylation, polyamine and quorum sensing phenomena.

Donald L. Trump, Professor, M.D., Johns Hopkins University. Novel therapeutic approaches to prostate and other adult solid tumors; vitamin D-based therapeutics for prevention and therapy for prostate cancer.

Xinjiang Wang, Assistant Professor, Ph.D., Weizmann Institute of Science, Rehovot, Israel.  Identification of regulators of tumor cell growth control through biochemical and cell-based approaches and development of targeted cancer therapeutics.

Michael Wong, Assistant Professor, M.D., Ph.D., University of Toronto. The interface between tumor and host with a particular emphasis on angiogenesis, tumor matrix and immune immodulation.